AR and prostate cancer: Recently, a series of LuCaP prostate cancer patient-derived xenograft (PDX) tumors were established, representing the major genomic and phenotypic features of the human disease, including amplification of AR, loss of TP53 and PTEN, and showing heterogeneity in responses to treatment of advanced PC [3].